See more : Manning & Napier, Inc. (MN) Income Statement Analysis – Financial Results
Complete financial analysis of vTv Therapeutics Inc. (VTVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of vTv Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Carborundum Universal Limited (CARBORUNIV.BO) Income Statement Analysis – Financial Results
- Playgon Games Inc. (DEAL.V) Income Statement Analysis – Financial Results
- iAnthus Capital Holdings, Inc. (IAN.CN) Income Statement Analysis – Financial Results
- Jash Engineering Limited (JASH.NS) Income Statement Analysis – Financial Results
- Oxford Lane Capital Corp. (OXLCO) Income Statement Analysis – Financial Results
vTv Therapeutics Inc. (VTVT)
About vTv Therapeutics Inc.
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 2.02M | 4.01M | 6.41M | 2.76M | 12.43M | 291.00K | 634.00K | 519.00K | 1.55M | 976.00K |
| Cost of Revenue | 13.60M | 92.00K | 89.00K | 11.02M | 15.12M | 23.04M | 39.64M | 45.75M | 29.58M | 18.73M | 25.43M |
| Gross Profit | -13.60M | 1.93M | 3.92M | -4.60M | -12.36M | -10.60M | -39.35M | -45.11M | -29.07M | -17.18M | -24.46M |
| Gross Profit Ratio | 0.00% | 95.44% | 97.78% | -71.73% | -447.00% | -85.26% | -13,521.99% | -7,115.77% | -5,600.19% | -1,109.10% | -2,505.94% |
| Research & Development | 13.60M | 12.36M | 13.32M | 11.02M | 15.12M | 23.04M | 39.64M | 45.75M | 29.58M | 18.73M | 25.43M |
| General & Administrative | 11.91M | 12.20M | 12.34M | 7.25M | 8.54M | 9.22M | 11.33M | 9.91M | 9.08M | 11.72M | 11.38M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.91M | 12.20M | 12.34M | 7.25M | 8.54M | 9.22M | 11.33M | 9.91M | 9.08M | 11.72M | 11.38M |
| Other Expenses | -13.60M | -2.67M | 4.06M | -270.00K | 828.00K | -592.00K | -190.00K | -22.00K | -2.97M | -1.13M | -534.00K |
| Operating Expenses | 11.91M | 24.56M | 25.67M | 18.27M | 23.66M | 32.26M | 50.97M | 55.65M | 38.66M | 30.45M | 36.81M |
| Cost & Expenses | 25.50M | 24.56M | 25.67M | 18.27M | 23.66M | 32.26M | 50.97M | 55.65M | 38.66M | 30.45M | 36.81M |
| Interest Income | 472.00K | 352.00K | 1.00K | 12.00K | 53.00K | 61.00K | 117.00K | 87.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.00K | 15.00K | 12.00K | 692.00K | 1.83M | 3.29M | 3.09M | 398.00K | 1.74M | 6.01M | 11.82M |
| Depreciation & Amortization | 90.00K | 92.00K | 89.00K | 94.00K | 39.00K | 218.00K | 197.00K | 265.00K | 501.00K | 864.00K | 1.09M |
| EBITDA | -25.41M | -24.77M | -17.52M | -12.02M | -19.97M | -20.14M | -50.56M | -54.69M | -38.87M | -29.23M | -35.30M |
| EBITDA Ratio | 0.00% | -1,231.81% | -439.55% | -188.81% | -723.99% | -163.70% | -17,441.58% | -8,667.98% | -7,349.13% | -1,882.44% | -3,614.86% |
| Operating Income | -25.50M | -22.54M | -21.66M | -11.85M | -20.89M | -19.82M | -50.68M | -55.02M | -38.14M | -28.90M | -35.83M |
| Operating Income Ratio | 0.00% | -1,116.95% | -540.87% | -184.78% | -755.86% | -159.43% | -17,416.49% | -8,678.23% | -7,349.13% | -1,865.53% | -3,671.41% |
| Total Other Income/Expenses | -464.00K | -2.33M | 4.05M | -950.00K | -946.00K | -3.82M | -3.17M | -333.00K | -2.97M | -7.20M | -12.37M |
| Income Before Tax | -25.97M | -24.87M | -17.62M | -12.80M | -21.84M | -23.65M | -53.85M | -55.35M | -41.11M | -36.10M | -48.20M |
| Income Before Tax Ratio | 0.00% | -1,232.56% | -439.85% | -199.59% | -790.09% | -190.16% | -18,504.12% | -8,730.76% | -7,920.42% | -2,330.60% | -4,938.83% |
| Income Tax Expense | 0.00 | 200.00K | 115.00K | -3.98M | 100.00K | 200.00K | 800.00K | -39.00M | -14.11M | 4.88M | 11.29M |
| Net Income | -20.25M | -25.07M | -17.73M | -8.83M | -21.94M | -7.91M | -16.14M | -16.35M | -27.50M | -36.10M | -48.20M |
| Net Income Ratio | 0.00% | -1,242.47% | -442.72% | -137.62% | -793.70% | -63.62% | -5,547.77% | -2,579.18% | -5,298.27% | -2,330.60% | -4,938.83% |
| EPS | -9.71 | -13.06 | -11.32 | -7.49 | -28.97 | -25.42 | -66.62 | -68.52 | -132.90 | -173.87 | -234.57 |
| EPS Diluted | -9.71 | -13.06 | -11.32 | -7.49 | -28.97 | -25.42 | -66.62 | -68.52 | -132.90 | -173.87 | -234.57 |
| Weighted Avg Shares Out | 2.08M | 1.92M | 1.57M | 1.18M | 757.30K | 311.23K | 242.33K | 238.64K | 206.91K | 207.63K | 205.49K |
| Weighted Avg Shares Out (Dil) | 2.08M | 1.92M | 1.57M | 1.18M | 757.30K | 311.23K | 242.33K | 238.64K | 206.91K | 207.63K | 205.49K |
vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
3 Biopharma Penny Stocks That Could be Millionaire Makers
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
Top 10 Biotech Penny Stocks to Watch in July 2021
Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today
vTv Therapeutics Shares Jump On Out-Licensing Agreement For Azeliragon In Cancer Settings
vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
What Are Penny Stocks? 4 to Buy [Or Sell] In 2021
VTv Therapeutics (VTVT) Reports Q1 Loss, Tops Revenue Estimates
vTv Therapeutics (VTVT) Gets Breakthrough Tag for Diabetes Drug
Source: https://incomestatements.info
Category: Stock Reports